Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 685 participants.

Also called NCT05099770

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 685 participants (planned count) (from the registry)
Sponsor
Prokidney (from the registry)
Registry
  • NCT NCT05099770
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Mexico, Puerto Rico, Taiwan (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05099770. Randomized; triple masking; primary purpose treatment. Start 2022-01-05 (actual); primary completion 2029-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Condition
Type 2 Diabetes Mellitus
Condition
Chronic Kidney Diseases
Intervention (Biological)
Renal Autologous Cell Therapy (REACT/ rilparencel)
Intervention (Procedure)
Sham Comparator
Lead sponsor
Prokidney (class: industry)

Record details

Record id
cardio:ct-nct05099770
Content hash
c9d69f667e90446ba1a11c0119270fc6b3dce0f2e3602fad79fc9d4b5a0911e9